Category:
Carcinomas
Cancer type:
Kidney
Descriptor:
Met expression
Reference Number:
1
Joseph, A. et al. Expression of scatter factor in human bladder carcinoma.
J Natl Cancer Inst 87, 372-7. (1995).
PubMed link
Reference Number:
60
Oh, R. R. et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.
Apmis 110, 229-38 (2002).
PubMed link
Reference Number:
61
Inoue, K. et al. Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth.
Virchows Arch 433, 511-5 (1998).
PubMed link
Reference Number:
62
Nakopoulou, L. et al. Immunodetection of c-met-oncogene's protein product in renal cell neoplasia.
Pathol Res Pract 193, 299-304 (1997).
PubMed link
Reference Number:
258
Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma.
J Urol 168:51-5 (2002).
PubMed link
Reference Number:
286
Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma.
J Urol 171, 2166-70 (2004)
PubMed link
Reference Number:
448
Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, Genina O, Pines M. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
J Urol. 174, 1527-31 (2005)
PubMed link
Reference Number:
492
Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.
Clin Cancer Res.
12, 4876-81 (2006)
PubMed link
Reference Number:
493
Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH. MET expression in sporadic renal cell carcinomas.
J Korean Med Sci.
21, 672-7 (2006)
PubMed link
Reference Number:
494
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas.
Cancer Res.
66, 4750-7 (2006)
PubMed link
Reference Number:
495
Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.
Cancer Res.
66, 3699-705 (2006)
PubMed link
Reference Number:
539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Cancer Sci.
98, 491-8 (2007)
PubMed link
Reference Number:
634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
J Biol Chem.
283, 2675-83 (2008)
PubMed link
Reference Number:
638
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Int J Oncol.
33, 271-6 (2008)
PubMed link
